Pipeline

Our pipeline of oncolytic immunotherapies is targeting specific colorectal cancer indications with both high prevalence and significant unmet need.
Product
Indication(s)
Principal Mechanism
Preclinical
Phase I
Phase II
Worldwide Rights
NG-350A

pMMR LARC1

FDA Fast-Track Designation
CD40 agonism

Worldwide Rights

Rest-of-World
Greater China

Transgene Payload: Secreted CD40 agonist monoclonal antibody

NG-348

mCRC2

Direct T-cell engagement

Worldwide Rights

Transgene Payload: Membrane bound CD80 and anti-CD3 scFv

Undisclosed

Undisclosed

CART-T targeting
& activation

Worldwide Rights

Undisclosed

Transgene Payload: Undisclosed

Product: NG-350A

Preclinical
Phase I
Phase II

Indication: pMMR LARC1 FDA Fast-Track Designation

Principle Mechanism: CD40 agonism

Transgene Payload: Secreted CD40 agonist monoclonal antibody

Worldwide Rights:

Rest-of-World
Greater China

Product: NG-348

Preclinical
Phase I
Phase II

Indication: mCRC2

Principle Mechanism: Direct T-cell engagement

Transgene Payload: Membrane bound CD80 and anti-CD3 scFv

Worldwide Rights:

Product: Undisclosed

Preclinical
Phase I
Phase II

Indication: Undisclosed

Principle Mechanism: CART-T targeting
& activation

Transgene Payload: Undisclosed

Worldwide Rights:

Undisclosed

1. Mismatch repair-proficient locally advanced rectal cancer (pMMR LARC); 2. Metastatic colorectal cancer (mCRC)

T-SIGn® therapeutics have been clinically evaluated as monotherapy and in combination with other immuno-oncology agents, demonstrating a consistent safety & tolerability profile in addition to promising preliminary efficacy.

Collaborations

In 2024, Akamis Bio entered into a licensing agreement granting Xuanzhu Biopharma the Greater China Region rights for NG-350A.
Akamis Bio is collaborating with an undisclosed partner using T-SIGn® therapeutics to drive local expression of a synthetic CAR to increase the efficacy and safety of CAR-T therapy for solid tumors.